Pan-Cancer analysis of clinical significance and associated molecular features of glycolysis

Yi-chen Liu
Guangxi Medical University

Peng Lin
Guangxi Medical University

Yu-jia Zhao
Guangxi Medical University

Lin-yong Wu
Guangxi Medical University

Yu-quan Wu
Guangxi Medical University

Jin-bo Peng
Guangxi Medical University

Hong Yang
Guangxi Medical University

Yun He (✉ heyun@stu.gxmu.edu.cn)
Guangxi Medical University

Research Article

Keywords: glycolysis, pan-cancer, multi-omics, immune evasion

Posted Date: February 18th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-194114/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at Bioengineered on January 1st, 2021. See the published version at https://doi.org/10.1080/21655979.2021.1955510.
Abstract

**Background** Tumor glycolysis acts as a major promoter of carcinogenesis and cancer progression. Given its complex mechanisms and interactions, a comprehensive analysis to reveal its clinical significance and molecular features is urgent.

**Materials and Methods** Based on a well-established glycolysis gene expression signature, we quantified 8633 patients across different cancer types from The Cancer Genome Atlas (TCGA) and evaluated their prognostic associations. High tumor glycolytic activity correlated with inferior overall survival in pan-cancer patients (hazard ratio: 1.70, 95% confidence interval: 1.20–2.40, \(P = 0.003\)). The prognostic value of glycolysis was stable regardless of clinical parameters and correlated with molecular subtypes. The prognostic significance of glycolysis was validated using another three independent datasets. In addition, genome, transcriptome, and proteome profiles were utilized to characterize distinctive molecular features associated with glycolysis.

**Results** Mechanistically, glycolysis fulfilled the fundamental needs of tumor proliferation in multiple ways. Exploration of the relationships between glycolysis and tumor infiltrating immune cells showed that glycolysis enabled immune evasion of tumor cells. Mammalian target of rapamycin inhibitors and dopamine receptor antagonists represent classes of compounds that can effectively reverse the glycolytic status of cancers.

**Conclusion** Our study provides an in-depth molecular understanding of tumor glycolysis and may have practical implications for clinical cancer therapy.

**Background**

Teleologically, carcinogenesis and tumor cell development are linked with and dependent on metabolic reprogramming to meet their needs in energy and macronutrient requirements (1, 2). In the alterations of metabolic reprogramming, the Warburg effect refers to the tendency of cancer cells to utilize glucose via glycolysis irrespective of oxygen availability (3, 4). Tumor glycolysis is a biological phenotype of most tumors and has served as the basis for cancer detection with positron emission tomography. Glycolysis has been associated with advanced tumor progression, treatment resistance, and poor clinical outcomes (5, 6). More importantly, it has also significantly been linked to many cancer molecular characteristics, including proliferation, angiogenesis, and immune evasion (7, 8). Hence, targeting tumor glycolysis is viewed as of major importance in cancer therapy(9). Nevertheless, a systematic characterization of the clinical and molecular characteristics of glycolysis is still needed.

In recent years, The Cancer Genome Atlas (TCGA) multi-omics data has driven the understanding of the molecular landscape of primary beyond individual molecular platforms by integrating genomic, transcriptomic, and proteomic characteristics and clinicopathological parameters (10). The tumor glycolysis status has also been linked to multiple layers of molecular alterations (11-14). Many excellent studies on the mechanisms of glycolysis have presented a clearer picture of tumor characteristics. For
example, upregulated tumor glycolysis was found to modulate T cell–mediated antitumor activity, thereby inhibiting melanoma patients’ response to adoptive T cell therapy (15). Glycolysis could also endow maintaining strong tumorigenic activity on transcription factors such as YAP/TAZ (16). Furthermore, metabolism of glycolytic modulates the translation of hypoxia-inducible factor 1-alpha (HIF1A) to control T cell responses to hypoxia (17). Taken together, these studies have established that glycolysis can lead to multiple layers of molecular changes and thus plays a pivotal role in cancer development. Yet, the underlying mechanistic details pertinent to the cancer glycolysis phenotype remain unclear.

With the availability of multi-omics data, we aimed to quantify glycolysis and reveal its prognostic value from pan-cancer perspectives. By multi-omics data integration of their genome, transcriptome, and proteome, we also aimed to identify molecular characteristics related to glycolysis. Finally, we aimed to identify specific molecular compounds that may eventually result in novel therapy strategies that can reverse the glycolytic status of cancers. These approaches provide an unprecedented opportunity to explore the biological characteristics of tumors in great depth.

**Materials And Methods**

**Classification of tumor glycolysis scores across various cancer types**

Molecular profiles including oncogenic signaling pathway, messenger RNA (mRNA) expression, and protein expression profiles were acquired from the TCGA pan-cancer project (https://gdc.cancer.gov/about-data/publications/pancanatlas). Genome-wide RNA sequencing (RNAseq) data profiles were obtained from the TCGA dataset using an Illumina HiSeq 2000 RNA Sequencing System. Cancer-relevant proteins and phosphoproteins were detected by reverse-phase protein arrays. The gene signature for glycolysis (REACTOME_GLYCOLYSIS) was defined based on 72 genes involved in glycolysis from the Molecular Signatures Database (MSigDB, http://software.broadinstitute.org/gsea/msigdb). To obtain more reliable results for survival analysis, only primary tumor samples with overall survival (OS) of no less than 30 days were included in further analysis. Finally, we analyzed 23 TCGA non-hematologic cancer types with a sample size ≥ 100. The glycolysis score for each tumor sample across cancer types was calculated using Gene Set Variation Analysis (GSVA) (18).

**Estimation of the prognostic value of glycolysis in pan-cancer**

Univariate Cox analysis was performed to explore the relationship between glycolysis scores and tumor patients’ OS. Then, meta-analysis was performed to integrate the univariate Cox survival analysis results into each type of cancer. Heterogeneity between individual studies was evaluated by the Q test: $I^2 > 50\%$ and/or $P \leq 0.05$ indicated significant heterogeneity. Random effects or fixed effects model was identified based on the heterogeneity analysis results. Meta-analysis was performed using Stata 14.0 (Stata
Corporation, College Station, TX, USA). To further explore variations in the effect of glycolysis on OS, subgroup analyses stratified by age, gender, and tumor stage were performed.

We further performed consensus cluster analysis to identify a global pattern of glycolysis across the 23 types of cancers using the ConsensusClusterPlus package in R software (19). Patients were grouped into two clusters according to glycolysis-related genes using two-class K-means clustering with the Euclidean distance. Principal component analysis (PCA) was used to observe the patients in the two clusters. The OS difference between the clusters was calculated by the Kaplan–Meier (K–M) method and the log-rank test.

Clinical and molecular characterizations related to glycolysis

We evaluated the glycolysis status for 10 canonical signaling pathways with frequent genetic alterations: (1) cell cycle, (2) Hippo, (3) Myc, (4) Notch, (5) oxidative stress response/nuclear factor erythroid 2-related factor 2 (Nrf2), (6) phosphoinositide 3-kinase (PI3K), (7) receptor tyrosine kinase (RTK)/RAS/mitogen-activated protein (MAP) kinase, (8) transforming growth factor-beta (TGF-β), (9) p53, and (10) β-catenin/Wnt signaling (20). A tumor sample was found to have changed based on genes involved in the pathways were found recurrently altered, recurrently mutated positions, known functional gene fusions/rearrangements and epigenetic silencing calls. Then, Mann–Whitney U tests were performed to estimate the difference in glycolysis scores between pathways with and without alterations.

We also computed the correlation between glycolysis scores and mRNA and protein expression profiles. Spearman's rank correlation was used to assess the correlation between glycolysis scores and molecular factors. Glycolysis-associated genes and proteins in each cancer type were determined as follows: Spearman's correlation |coefficient| > 0.3 and P < 0.05. We found that genes significantly positively correlated with glycolysis scores in at least 15 cancer types were glycolysis-associated genes. Glycolysis-associated genes were further subjected to a process of gene ontology (GO) classification analysis using the R package clusterProfiler (21). To ascertain functional interactions between these glycolysis-related genes and found hub genes, protein–protein interaction (PPI) networks were constructed using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database version 11.0 (required interaction score: >0.9)(22).

Exploration of the relation between increased glycolysis and immune evasion

Growing evidence suggests that increased glycolysis actively interferes with immune cell functions. Thus, we aimed to unveil the association between glycolysis and immune status. The tumor immune microenvironment is an executor of immunotherapy. Using CIBERSORT, we obtained 22 types of immune cells in 6 classes from the TCGA pan-cancer project: (1) lymphocytes (B cells naïve, B cells memory, T cells CD4 naïve, T cells CD4 memory resting, T cells CD4 memory activated, T cells follicular helper, T
cells regulatory Tregs, T cells gamma delta, T cells CD8, NK cells resting, NK cells activated, plasma cells); (2) macrophages (monocytes, macrophages M0, macrophages M1, macrophages M2); (3) dendritic cells (dendritic cells resting, dendritic cells activated); (4) mast cells (mast cells resting, mast cells activated); (5) neutrophils and (6) eosinophils (23).

Antigen-specific T cell receptor and B cell receptor repertoires are critical for the the process of malignant cells recognition and may reflect a robust antitumor response comprising a large number of antigen-specific adaptive immune cells.

Owing to the complexity of immune evasion, we also explored the associations between glycolysis and DNA damage, including copy number variation (CNV) burden (in terms both of number of segments and of fraction of genome alterations), aneuploidy, loss of heterozygosity (LOH), homologous recombination deficiency (HRD), predicted neoantigen number (including single-nucleotide variant [SNV] and indel neoantigens), and intratumor heterogeneity (ITH). The detailed process of quantitative analysis of these indicators was described in a previous study (29628290).

Compounds targeting cancer glycolysis

To explore which molecules could be effective in cancer-inhibitory glycolytic activity, we performed Connectivity Map (Cmap) analysis (24). Cmap is a public online database similar to Gene Set Enrichment Analysis (GSEA), which predicts target drugs based on a query signature. Gene symbols were mapped to the HG-U133A probe set GPL96 platform ID. We identified 500 genes most positively associated and 500 genes most negatively associated with glycolysis scores to query drugs matching the “reference” signature. Compounds with an enrichment score <0 and a P-value <0.05 were identified as glycolysis antagonist drugs.

Results

Increased tumor glycolytic activity indicates inferior survival in various cancers

A total of 23 types of cancer in 8633 cases were identified in the survival analysis of glycolysis score and OS. A 72-gene expression signature was used to calculate the glycolysis scores. Univariate Cox analysis showed that increased tumor glycolytic activity was significantly associated with lower OS in six types of cancers: liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), head and neck squamous cell carcinoma (HNSC), sarcoma (SARC), brain lower grade glioma (LGG), and pancreatic adenocarcinoma (PAAD) (Table 1). A list of the TCGA cancer type abbreviations is available at https://gdc.cancer.gov/resources-tcga-users/tcga-code-tables/tcga-study-abbreviations. To evaluate the prognostic value of glycolysis in pan-cancer patients, we combined HRs for OS. Increased tumor glycolytic activity correlated with inferior OS (HR: 1.70, 95% confidence interval: 1.20–2.40, P = 0.003; Figure 1A). Furthermore, we conducted subgroup analysis to observe the prognostic value of glycolysis in
different clinicopathological parameters. We also performed analyses of the effects of glycolysis on OS by subgroups defined by age (<60, ≥60 years), gender (female, male), and pathological stage (early stage, advanced stage). Subgroup analysis revealed that glycolysis is widespread and acts as an unfavorable factor of tumor patients’ prognosis (Table 2).

Table 1. Univariate Cox analysis of glycolysis score.
| Study   | N   | Hazard ratio | 95% confidence interval | P-value |
|---------|-----|--------------|-------------------------|---------|
| BLCA    | 399 | 1.793        | 0.954-3.367             | 0.070   |
| BRCA    | 1052| 1.894        | 0.974-3.684             | 0.060   |
| CESC    | 273 | 2.591        | 0.931-7.214             | 0.068   |
| COAD    | 426 | 0.672        | 0.277-1.631             | 0.380   |
| ESCA    | 178 | 0.985        | 0.404-2.399             | 0.973   |
| GBM     | 146 | 1.034        | 0.400-2.676             | 0.945   |
| HNSC    | 512 | 2.819        | 1.553-5.117             | 0.001   |
| KIRC    | 518 | 0.972        | 0.460-2.053             | 0.940   |
| KIRP    | 278 | 3.941        | 0.840-18.483            | 0.082   |
| LGG     | 481 | 3.276        | 1.161-9.243             | 0.025   |
| LIHC    | 343 | 8.862        | 3.471-22.628            | 5.00E-06|
| LUAD    | 492 | 3.460        | 1.940-6.173             | 2.60E-05|
| LUSC    | 474 | 0.714        | 0.401-1.271             | 0.252   |
| OV      | 295 | 0.724        | 0.316-1.658             | 0.444   |
| PAAD    | 172 | 3.034        | 1.113-8.271             | 0.030   |
| PCPG    | 172 | 10.703       | 0.112-1020.485          | 0.308   |
| PRAD    | 494 | 20.645       | 0.705-604.846           | 0.079   |
| READ    | 153 | 0.243        | 0.042-1.403             | 0.114   |
| SARC    | 255 | 3.723        | 1.571-8.825             | 0.003   |
| STAD    | 375 | 0.609        | 0.341-1.087             | 0.093   |
| TGCT    | 130 | 0.787        | 0.015-40.206            | 0.905   |
| THCA    | 502 | 4.915        | 0.402-60.072            | 0.213   |
| THYM    | 118 | 0.112        | 0.008-1.580             | 0.105   |
| UCEC    | 513 | 1.389        | 0.622-3.100             | 0.423   |

Table 2. Subgroup analysis for the prognostic value of glycolysis score.
| Parameters | Types of cancer | No. of patients | HR (95%CI)       | P-value | Model       |
|------------|-----------------|-----------------|------------------|---------|-------------|
| Age        |                 |                 |                  |         |             |
| Age <60    | 23              | 4034            | 1.82 (1.08-3.08) | 0.025   | Random effects |
| Age ≥60    | 22              | 4575            | 1.50 (1.01-2.22) | 0.044   | Random effects |
| Gender     |                 |                 |                  |         |             |
| Female     | 21              | 4477            | 1.62 (1.25-2.11) | <0.001  | Fixed effects |
| Male       | 20              | 4156            | 1.81 (1.11-2.93) | 0.016   | Random effects |
| Stage      |                 |                 |                  |         |             |
| I/II       | 15              | 3631            | 1.82 (1.07-3.08) | 0.027   | Random effects |
| III/IV     | 14              | 2078            | 1.56 (1.17-2.10) | 0.003   | Fixed effects |

To identify the clinical parameters associated with glycolysis status in cancer, we compared the glycolysis scores between different parameters. In many types of cancers, the glycolysis scores displayed a different status for different clinical features (Figure 1B). For example, there were significant differences between early and advanced stage in seven types of cancer. We further explored the status of glycolysis in different molecular subtypes of tumors (Figure 1C–F). In the case of breast cancer, the glycolysis score was lowest in the luminal A subtype, which is the subtype with the best prognosis.

The prognostic value of glycolysis was most significant in LIHC. Hence, three independent cohorts were used to validate the results: GSE14520 (N = 242)(25) and GSE54236 (N = 78)(26), acquired from the Gene Expression Omnibus (GEO) repository, and the LIRI-JP dataset (N = 229)(27), downloaded from the International Cancer Genome Consortium (ICGC) database. The glycolysis score was calculated using GSVA in hepatocellular carcinoma patients with OS of no less than 30 days. Based on the median value of the glycolysis score, LIHC patients were divided into high- and low-glycolysis groups. The patients in the high glycolysis group exhibited lower OS (Figure 2).

**Global patterns of glycolysis signatures across cancer types**

Based on the tumor expression levels of 72 glycolysis genes, 2047 patients were assigned to a group of high expression of glycolysis-associated genes, and 6585 patients were assigned to a group of low expression of glycolysis-associated genes (Figure 3A). The PCA plot showed that the two clusters were markedly different (Figure 3B). The K–M survival plot showed that patients in the high glycolysis group had inferior OS than patients grouped into the low glycolysis group (Figure 3C). The global expression profiles also indicated differences between the two groups; different glycolysis levels significantly correlated with different clinical parameters (Figure 3D). Notably, different types of tumors accounted for different high-to-low glycolysis group ratios. The ratio of high to low glycolysis group was highest in
kidney renal clear cell carcinoma (KIRC) patients and lowest in prostate adenocarcinoma (PRAD) and thyroid cancer (THCA) patients (Figure 3E).

**Glycolysis effects on multidimensional molecular factors**

Signaling pathways are characterized by frequent somatic alterations and complex interactions with each other. A systematic characterization and exploration of the relationships between oncogenic signaling pathway alterations and glycolysis is becoming meaningful. The glycolysis scores were significantly different between many signaling pathways with and without alterations in different types of cancers (Figure 4A). Glycolysis was upregulated in the PI3K signaling pathway alterations group compared with the no alterations group in 12 types of cancer, and in the cell cycle, tumor protein 53 (TP53), and Hippo signaling pathway alterations group compared with the no alterations group in 10 types of cancer (Figure 4B).

We also explored the glycolysis-associated mRNA expression profiles, as mRNA expression serves as a link between genetic alterations and protein actions. Genes positively correlated with glycolysis in more than 15 cancer types were subjected to functional enrichment analysis. We found that these genes were mainly involved in cell proliferation–associated biological processes and energy-related molecular functions (Figure 5A). The pathway annotations indicated that “Cell cycle” was the most significant relevant term related to glycolysis alterations (Figure 5B). The PPI network analysis also suggested that some genes important in the cell cycle, such as CDK1 and PLK1, were the cores in the network (Figure 5C).

At the protein level, some findings verified the results based on transcriptomics data and led to further discoveries (Figure 6A). Cyclin B1 was significantly positively associated with the glycolysis score in 16 types of tumors. FOXO3A PS318S321, and P27 were markedly negatively related to the glycolysis score in seven types of tumors (Figure 6B).

**Glycolytic activity likely positively correlates with immune evasion**

Tumor infiltration of lymphocytes is one of the key mechanisms in cancer progression and therapeutic responses. Spearman’s correlation analysis showed that the glycolysis scores significantly negatively correlated with the infiltration of lymphocytes and positively correlated with the infiltration of macrophages and neutrophils (Figure 6). Programmed death-ligand 1 (PD-L1) expression was higher in patients with high glycolysis scores than those with low scores. Increased glycolysis generally correlated
with increased T helper (TH) 2 cell infiltration, and TH1 cell infiltration showed the opposite correlation in most types of cancers (Figure 7).

We also explored the relationship between glycolytic activity and genomic instability. Glycolysis was related to measures of DNA damage, including copy number variation (CNV) burden, aneuploidy, homology directed repair (HRD), and intratumor genetic heterogeneity (ITH). Neoantigen load was also associated with higher glycolysis. All these findings suggested that glycolysis was markedly associated with high genomic instability (Figure 8).

Compounds potentially capable of targeting glycolysis

The Cmap online tool was used to discover relationships between genes, compounds, and biological processes and search for valuable targeted molecular compounds for glycolysis. We identified 75 that closely related with glycolysis in not less than 10 cancer types. Sirolimus and LY-294002 as mammalian target of rapamycin (mTOR) inhibitors were found to target glycolysis in all 23 types of cancers (Figure 9A). Cmap mode-of-action (MoA) analysis revealed that 42 mechanisms of action were shared by 44 of the compounds (Figure 9B). Nine compounds shared the MoA of dopamine receptor antagonists.

Discussion

In this study, we systematically analyzed the prognostic value and effects of glycolysis on molecular signatures in 8633 primary human tumors across 23 cancer types. We gained insight into the relationship between glycolysis and low pan-cancer tumor survival. Our study provides a comprehensive view of glycolysis-associated molecular signatures, including genome, transcriptome, and proteome data. We provided a description of the relation between glycolysis and immune evasion from immune cell infiltrations and immune-related indicators. And our exploration led to potentially actionable compounds as candidates for alternative metabolism therapy for solid tumors. Our integrative analysis further suggests that glycolysis can impact tumors in many ways.

Metabolic reprogramming fulfills tumors’ energy/nutrient requirements and is considered a hallmark of cancer (2). Previous studies found that a higher glycolysis level significantly correlates with a higher risk of adverse events or death in many types of cancers, including head and neck (28), lung (29), and esophageal cancer(30). With advancements in next-generation technologies and public cancer databases, it is now possible to comprehensively analyze the prognostic value of glycolysis in pan-cancer. We found that increased tumor glycolytic activity is associated with poor clinical outcomes in pan-cancer samples. This finding is consistent with recent work demonstrating that high glycolytic activity positively correlates with higher death risk. The prognostic significance was stable in patients
with different clinicopathological. These results indicate fundamental and universal traits of glycolysis in cancer prognosis.

By integrating multi-omics data, we observed that oncogenic glycolysis to be related with some molecular characteristics. Multi-omics analysis can link and integrate multilayered information and provide more reliable and accurate results than single platform analysis. The first one is perturbations in oncogenic signaling pathways. Several important signaling pathways have been identified as frequently genetically altered in cancer (31). Patients with PI3K, cell cycle, and TP53 pathway alterations were found to have high glycolysis scores in multiple tumor types. At the transcriptome level, we identified glycolysis-associated genes, and subsequent gene functional enrichment analysis also indicated essential cell cycle and proliferation processes. Proteomics analysis revealed that cell cycle regulatory protein cyclin B1 is an important participant in glycolysis process. Different multi-omics data suggested that glycolysis is inextricably related with tumor proliferation. The most basic characteristic of cancer cells is continuous proliferation (2). It can be said that glycolysis first meets the most basic requirements of tumors.

Carcinogenesis and cancer progression modulated by tumor glycolysis have aroused considerable interest. However, the immune regulatory role of glycolysis is still unclear. The high concentration of lactate produced by the glycolytic process in TME suppresses the anticancer immune cells by disturbing their intracellular pH (32, 33). Furthermore, cancer glycolytic activity competes with immune cells for glucose uptake (34, 35), whereby cancer cells effectively achieve immune evasion. We found that increased tumor glycolytic activity is related to poor tumor lymphocyte infiltration in the majority of cancer types. Previous studies also found that it is inversely associated with tumor infiltration of T cells in melanoma, non-small-cell lung carcinoma (NSCLC), and HNSC samples (15, 36). As for T helper cells, increased glycolysis scores strongly correlated with high TH2 and low TH1 cell infiltration, which is an interesting phenomenon. Preferential accumulation of immunosuppressive and TH2 cells, rather than antitumor TH1 cells, have been found to be indispensable in tumor immune evasion (37, 38). Similarly, the relationships between glycolytic activity and the PD-L immune checkpoint and TCR richness also suggest that increased glycolysis promotes tumor proliferation by immune evasion.

We queried Cmap using the gene expression signatures from glycolysis-associated gene analysis. Perhaps surprisingly, the Cmap analysis, which is based on a limited number of treated cell lines, very precisely selected drugs that have been shown to affect cancer metabolism with specificity. MTOR inhibitors were significantly enriched in all cancer types and have been reported to inhibit glycolysis-related tumorigenicity (39). Interestingly, mTOR actively participates in T cell function and activity (40). Dopamine receptor antagonists, the most frequent compounds in the Cmap analysis, also showed a capacity to inhibit tumor progression (41). These translational analyses may provide alternative approaches for metabolic cancer treatment.

Conclusion
In summary, glycolysis could be a reliable predictor of clinical outcomes of tumors. This study also provides a comprehensive catalogue of molecular alterations associated with glycolysis and contributes to our understanding of glycolysis, perhaps leading to effective survival prediction, treatment decision-making, and target therapy identification.

**Declarations**

**Ethics approval and consent to participate**

This study was approved by the First Affiliated Hospital of Guangxi Medical University as a retrospective study, and the requirement for informed consent was waived. All procedures performed in studies involving human participants were in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments.

**Consent for publication**

None.

**Availability of data and materials**

The datasets used during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This study has received funding by the Fund of National Natural Science Foundation of China (grant no. NSFC81960329 and no. NSFC81860319).

**Authors' contributions**

(I) Study design: Yi-chen Liu, Peng Lin; Yu-jia Zhao, and Lin-yong Wu; (II) Administrative support: Hong Yang and Yun He; (III) Collection and assembly of data: Yu-quan Wu and Jin-bo Peng; (IV) Data analysis
Acknowledgements

The results shown here are part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.

References

1. Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi PL, Wang Y, et al. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell Rep. 2018;23(1):255-69 e4.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
3. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-14.
4. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-33.
5. Yu M, Chen S, Hong W, Gu Y, Huang B, Lin Y, et al. Prognostic role of glycolysis for cancer outcome: evidence from 86 studies. J Cancer Res Clin Oncol. 2019;145(4):967-99.
6. Han S, Kim H, Kim YJ, Suh CH, Woo S. Prognostic Value of Volume-Based Metabolic Parameters of (18)F-FDG PET/CT in Uterine Cervical Cancer: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2018;211(5):1112-21.
7. Jones W, Bianchi K. Aerobic glycolysis: beyond proliferation. Front Immunol. 2015;6:227.
8. Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013;123(9):3685-92.
9. Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013;12:152.
10. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158(4):929-44.
11. Harami-Papp H, Pongor LS, Munkacsy G, Horvath G, Nagy AM, Ambrus A, et al. TP53 mutation hits energy metabolism and increases glycolysis in breast cancer. Oncotarget. 2016;7(41):67183-95.
12. Zhou Y, Niu W, Luo Y, Li H, Xie Y, Wang H, et al. p53/Lactate dehydrogenase A axis negatively regulates aerobic glycolysis and tumor progression in breast cancer expressing wild-type p53. Cancer Sci. 2019;110(3):939-49.
13. Qian X, Li X, Shi Z, Xia Y, Cai Q, Xu D, et al. PTEN Suppresses Glycolysis by Dephosphorylating and Inhibiting Autophosphorylated PGK1. Mol Cell. 2019;76(3):516-27 e7.
14. Hua Q, Jin M, Mi B, Xu F, Li T, Zhao L, et al. LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis. J Hematol Oncol. 2019;12(1):91.
15. Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, et al. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab. 2018;27(5):977-87 e4.
16. Enzo E, Santinon G, Pocaterra A, Aragona M, Bresolin S, Forcato M, et al. Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO J. 2015;34(10):1349-70.
17. Xu Y, Chaudhury A, Zhang M, Savoldo B, Metelitsa LS, Rodgers J, et al. Glycolysis determines dichotomous regulation of T cell subsets in hypoxia. J Clin Invest. 2016;126(7):2678-88.
18. Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.
19. Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572-3.
20. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018;173(2):321-37 e10.
21. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284-7.
22. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607-D13.
23. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The Immune Landscape of Cancer. Immunity. 2018;48(4):812-30 e14.
24. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929-35.
25. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010;70(24):10202-12.
26. Villa E, Critelli R, Lei B, Marzocchi G, Camma C, Giannelli G, et al. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut. 2016;65(5):861-9.
27. Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M, Shiraishi Y, et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet. 2016;48(5):500-9.
28. Pak K, Cheon GJ, Nam HY, Kim SJ, Kang KW, Chung JK, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis. J Nucl Med. 2014;55(6):884-90.

29. Im HJ, Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, et al. Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis. Eur J Nucl Med Mol Imaging. 2015;42(2):241-51.

30. Han S, Kim YJ, Woo S, Suh CH, Lee JJ. Prognostic Value of Volumetric Parameters of Pretreatment 18F-FDG PET/CT in Esophageal Cancer: A Systematic Review and Meta-analysis. Clin Nucl Med. 2018;43(12):887-94.

31. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10(8):789-99.

32. Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity. 2002;16(6):769-77.

33. Gottfried E, Kunz-Schughart LA, Ebner S, Mueller-Klieser W, Hoves S, Andreesen R, et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood. 2006;107(5):2013-21.

34. Husain Z, Seth P, Sukhatme VP. Tumor-derived lactate and myeloid-derived suppressor cells: Linking metabolism to cancer immunology. Oncoimmunology. 2013;2(11):e26383.

35. Husain Z, Huang Y, Seth P, Sukhatme VP. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J Immunol. 2013;191(3):1486-95.

36. Ottensmeier CH, Perry KL, Harden EL, Stasakova J, Jenei V, Fleming J, et al. Upregulated Glucose Metabolism Correlates Inversely with CD8+ T-cell Infiltration and Survival in Squamous Cell Carcinoma. Cancer Res. 2016;76(14):4136-48.

37. Gu-Trantien C, Loi S, Garraud S, Equeter C, Libin M, de Wind A, et al. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013;123(7):2873-92.

38. Ruffell B, DeNardo DG, Affara NI, Coussens LM. Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev. 2010;21(1):3-10.

39. Jiang S, Zou Z, Nie P, Wen R, Xiao Y, Tang J. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells. PLoS One. 2015;10(7):e0132880.

40. Myers DR, Wheeler B, Roose JP. mTOR and other effector kinase signals that impact T cell function and activity. Immunol Rev. 2019;291(1):134-53.

41. Dolma S, Selvadurai HJ, Lan X, Lee L, Kushida M, Voisin V, et al. Inhibition of Dopamine Receptor D4 Impedes Autophagic Flux, Proliferation, and Survival of Glioblastoma Stem Cells. Cancer Cell. 2016;29(6):859-73.

Figures
Figure 1

The prognostic value of glycolysis in pan-cancer patients. (A) Forest plot of the correlation between glycolysis levels and OS of pan-cancer patients; (B) Heatmap shows P-values (including age, gender, pathologic stage, and histological grade) with significance (P < 0.05, red); (C–F) Highlight of tumor molecular subtypes that exhibit strong correlations with glycolysis.
Figure 2

Validation of the prognostic value of hepatocellular carcinoma (HCC) in three independent cohorts. (A) GSE14520; (B) GSE54236; (C) LIRI-JP.

Figure 3

Exploration of metabolism-driven cancer types. (A) Patients were divided into high- and low- glycolysis groups based on the gene expression of 72 signature genes generated by K-means clustering; (B) Principal component analysis plot indicates that the two subgroups have distinct glycolysis gene expression profiles; (C) Kaplan–Meier survival analysis curves for the two patient clusters; (D) Heatmap
of the 8633 patients grouped by cluster, with annotations associated with each cluster; (E) The ratio of patients with high and low glycolysis in different cancer types.

Figure 4

Associations between glycolysis and 10 oncogenic signaling pathway alterations. (A) Heatmap of glycolysis scores and pathway alterations; (B) Heatmap showing P-values (Mann–Whitney U test). Red indicates that the glycolysis score is upregulated, while blue indicates that it is downregulated in the pathway alteration group.
Figure 5

Gene functional enrichment analysis of glycolysis-associated genes. (A) Gene ontology of glycolysis-associated genes; (B) Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of glycolysis-associated genes; (C) Protein–protein interaction (PPI) network of glycolysis-associated genes.
Figure 6

Correlation network of glycolysis-related proteins. (A) Red lines show proteins positively related to glycolysis, while blue lines show proteins negatively related to glycolysis; (B) Bar plot indicates that cyclin B1 positively correlates with glycolysis in 16 types of cancer.

Figure 7

Associations between glycolysis and immune cell infiltrations.
**Figure 8**

Associations between glycolysis and immune-related index and genomic instability indicators.
Figure 9

Correlation of glycolysis with drug resistance: Connectivity Map analysis. (A) Heatmap showing a negative enrichment score of each compound from Cmap for each cancer type; (B) Heatmap showing each Cmap compound (perturbagen) that shares mechanisms of action (rows) and sorted by descending number of compounds with shared mechanisms of action.